secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001193125-24-166938
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics shareholders elect directors, ratify PwC, approve officer exculpation amendment at 2024 annual meeting
--------------------------------------------------------------------------------

- 78.31% quorum with 23,360,239 shares represented; all three Class II director nominees elected.
- Margaret FitzPatrick, Patricia Martin, Melvin Spigelman each received over 17.7M votes for.
- PricewaterhouseCoopers LLP ratified as auditor: 23,344,330 for, 12,786 against.
- Amendment to certificate of incorporation for officer exculpation approved: 18,416,318 for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524166938/0001193125-24-166938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524166938/d860451d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-166938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer